Multidrug-Loaded Lipid Nanoemulsions for the Combinatorial Treatment of Cerebral Cavernous Malformation Disease
Related Experiment Video
Updated: Aug 9, 2025
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Andrea Perrelli1,2,3, Annalisa Bozza4, Chiara Ferraris1,2
1Department of Clinical and Biological Sciences, University of Torino, 10043 Orbassano, TO, Italy.
Abstract:
Cerebral cavernous malformation (CCM) or cavernoma is a major vascular disease of genetic origin, whose main phenotypes occur in the central nervous system, and is currently devoid of pharmacological therapeutic strategies. Cavernomas can remain asymptomatic during a lifetime or manifest with a wide range of symptoms, including recurrent headaches, seizures, strokes, and intracerebral hemorrhages. Loss-of-function mutations in KRIT1/CCM1 are responsible for more than 50% of all familial cases, and have been clearly shown to affect cellular junctions, redox homeostasis, inflammatory responses, and angiogenesis. In this study, we investigated the therapeutic effects of multidrug-loaded lipid nanoemulsions in rescuing the pathological phenotype of CCM disease. The pro-autophagic rapamycin, antioxidant avenanthramide, and antiangiogenic bevacizumab were loaded into nanoemulsions, with the aim of reducing the major molecular dysfunctions associated with cavernomas. Through Western blot analysis of biomarkers in an in vitro CCM model, we demonstrated that drug-loaded lipid nanoemulsions rescue antioxidant responses, reactivate autophagy, and reduce the effect of pro-angiogenic factors better than the free drugs. Our results show the importance of developing a combinatorial preventive and therapeutic approach to reduce the risk of lesion formation and inhibit or completely revert the multiple hallmarks that characterize the pathogenesis and progression of cavernomas.
Insights
Novel lipid nanoemulsions loaded with rapamycin, avenanthramide, and bevacizumab show promise for treating cerebral cavernous malformation (CCM). This combinatorial therapy effectively targets key molecular pathways, offering a potential new strategy for this genetic vascular disease.
Area of Science:
- Neurovascular Diseases
- Nanomedicine
- Pharmacology
Background:
- Cerebral cavernous malformation (CCM) is a genetic vascular disorder affecting the central nervous system, characterized by lesions that can cause seizures, strokes, and hemorrhages.
- Current therapeutic strategies for CCM are limited, despite known genetic links to KRIT1/CCM1 mutations impacting cellular junctions, redox balance, inflammation, and angiogenesis.
- CCM pathogenesis involves multiple molecular dysfunctions, necessitating a multifaceted therapeutic approach.
Purpose of the Study:
- To investigate the therapeutic potential of multidrug-loaded lipid nanoemulsions for treating cerebral cavernous malformation (CCM).
- To assess the combined effects of rapamycin (pro-autophagic), avenanthramide (antioxidant), and bevacizumab (antiangiogenic) delivered via nanoemulsions.
- To evaluate the nanoemulsion's ability to counteract CCM-associated molecular pathologies.
Main Methods:
- Development of lipid nanoemulsions encapsulating rapamycin, avenanthramide, and bevacizumab.
- Utilized an in vitro model of cerebral cavernous malformation (CCM).
- Employed Western blot analysis to assess key biomarkers related to antioxidant response, autophagy, and angiogenesis.
Main Results:
- Drug-loaded lipid nanoemulsions demonstrated superior efficacy compared to free drugs in an in vitro CCM model.
- Nanoemulsions successfully rescued antioxidant responses, reactivated autophagy, and reduced pro-angiogenic factor effects.
- The combined therapeutic approach within nanoemulsions effectively addressed multiple molecular hallmarks of CCM.
Conclusions:
- Multidrug-loaded lipid nanoemulsions represent a promising therapeutic strategy for cerebral cavernous malformation (CCM).
- This combinatorial approach effectively targets key pathological pathways in CCM, including redox homeostasis, autophagy, and angiogenesis.
- Further development of such nanoemulsion-based therapies could offer a novel preventive and treatment option for CCM, potentially inhibiting or reversing disease progression.
